Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

Deal to sell Yandex to a consortium of Russian investors may fall apart

6/23/23 YNDX

Tinkoff plans to securitize mortgage portfolio

6/23/23 T

EU sanctions will not affect the plans of Positive Technologies

6/23/23 POSI

The AbbVie announced a quarterly dividend

6/23/23 ABBV

Positive Technologies fell under the sanctions of the European Union

6/23/23 POSI

Cherkizovo will invest ₽5 billion in the modernization of Altai Broiler

6/23/23 GCHE

Seligdar starts construction of the Mill at Khvoynoye

6/23/23 SELG

Fix Price opened its 6,000th store in Russia

6/23/23 FIXP

Shareholders of Bashneft approved dividends for 2022

6/23/23 BANE

Number of rides on Whoosh scooters doubled

6/23/23 WUSH